Trebananib
Based on 1 Customer Validation
Trebananib (2xCon4C) is an Fc fusion peptibody. Trebananib exerts its effects by blocking the binding of angiopoietin 1 (Ang1) and angiopoietin 2 (Ang2) to the TIE2 receptor. Trebananib has anti-angiogenic and anti-tumor activities.
For research use only. We do not sell to patients.
- Purity: ≥99.0%
- CAS No.: 894356-79-7
- Molecular Weight:63.25 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wild-type male ICR SCID mice (6-8 weeks old) with patient-derived xenograft (PDX) models of ccRCC[3]
-
Dosage:5.6 mg/k
-
Administration:Intraperitoneal injection; twice a week
-
Result:Significantly reduced lung metastases and M2 macrophage infiltration.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IGHG1 Fc (Fragment constant)-[peptide 14-mer-peptide 14-mer]2
ELISA, FACS, Functional assay
-
Immobilized Angiopoietin-2 Protein, Human can bind Trebananib. The EC50 for this effect is 10.67 ng/mL.
Chemical Information
-
CAS No. 894356-79-7
-
Appearance Liquid
-
Molecular Weight 63.25 kDa
-
Color Colorless to light yellow
-
SMILES
[Trebananib]
-
Synonyms
2xCon4C; AMG 386
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (257 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Moore KN, et al. A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial. Gynecol Oncol. 2015 Sep;138(3):513-8. [Content Brief]
[2]. Herbst RS, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol. 2009 Jul 20;27(21):3557-65. [Content Brief]
[3]. Elbanna M, et al. Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma. Mol Cancer Ther. 2020 Jan;19(1):147-156. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz